ST Tian Sheng released its 2026 interim report. Operating revenue was 233 million yuan, up 0.3 percent year on year. Net profit attributable to the parent swung from a loss of 36.71 million yuan in the same period last year to a loss of 24.17 million yuan, narrowing the deficit. Net profit attributable to the parent after deducting non-recurring items swung from a loss of 40.93 million yuan a year earlier to a loss of 27.24 million yuan, also narrowing the deficit. Net operating cash flow was 44.36 million yuan, up 74.9 percent year on year. In the second quarter, operating revenue was 101 million yuan, down 13.4 percent year on year. Net profit attributable to the parent swung from a loss of 24.3 million yuan in the same period last year to a loss of 14.39 million yuan, narrowing the deficit. Net profit attributable to the parent after deducting non-recurring items swung from a loss of 27.23 million yuan a year earlier to a loss of 15.18 million yuan, also narrowing the deficit. As of the end of the second quarter, total assets stood at 2.569 billion yuan, down 2.9 percent from the end of the previous year. Net assets attributable to the parent were 1.927 billion yuan, down 1.2 percent from the end of the previous year. In the interim report, the company said its overall operations face multiple risks and challenges, including medical insurance cost controls, centralized drug procurement and stricter industry regulation, and it will continue to focus on innovation-driven development and compliant operations.
Tiansheng Pharmaceutical Group Co LtdCompany reports narrowed but still significant losses, with revenue declining in Q2 and ongoing operational risks.
